Clinical trials: End-stage Liver Disease (ESLD)
End-stage Liver Disease (ESLD), Acute Liver Failure
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe
Machine perfusion (MP) has become routine clinical practice in liver transplantation. However, as the field has matured, direct randomized comparisons between distinct MP modalities have become increasingly impractical, given…
- Conditions
- End-stage Liver Disease (ESLD), Acute Liver Failure, Liver Cirrhosis, Liver Transplantation
- Trial name
- REFRAME-MP (NCT07585890)
- Testing
- Endischemic hypothermic oxygenated machine perfusion (any device), Endischemic (back-to-base) normothermic machine perfusion (any device), Continuous (device-to-donor) normothermic machine perfusion (any device)
- Where
- 37 sites in Austria, Belgium and 8 more
- Volunteers
- 10,000 people
- Sponsor
- University Medical Center Groningen
End-stage Liver Disease (ESLD), Cirrhosis, Liver
RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
The purpose of this study is to assess the safety and efficacy of RTX001 in patients with end-stage liver disease. This study is the first time RTX001, a macrophage cell therapy engineered to have an anti-inflammatory and…
- Conditions
- End-stage Liver Disease (ESLD), Cirrhosis, Liver, Cirrhosis, Decompensated, Liver Diseases
- Trial name
- EMERALD (NCT06823713)
- Testing
- RTX001
- Where
- 15 sites in Spain, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Resolution Therapeutics Limited
Liver Transplantation (LT), End-stage Liver Disease (ESLD)
Restrictive Fluid Management In Liver Transplantation (REFIL)
The goal of the REFIL-2 study is to evaluate the effectiveness of a low splanchnic blood volume restrictive fluid management strategy (a strategy that involves limiting fluid administration and prioritizing the use of medications…
- Trial name
- REFIL-2 (NCT07695363)
- Testing
- Low splanchnic blood volume restrictive fluid management strategy, Phlebotomy, Optimized cardiac output liberal fluid management strategy
- Where
- 4 sites in Canada
- Volunteers
- 866 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Liver Transplantation, End-stage Liver Disease (ESLD)
Restrictive Fluid Management In Liver Transplantation (REFIL) - Pilot
Hypothesis: A Canadian multicentre clinical trial is feasible. Study Design: Multicenter internal pilot parallel arm randomized controlled trial.
- Trial name
- REFIL-1 (NCT05647733)
- Testing
- Low splanchnic blood volume restrictive fluid management strategy, Optimized cardiac output liberal fluid management strategy, Phlebotomy
- Where
- 4 sites in Canada
- Volunteers
- 138 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
End-stage Liver Disease (ESLD), Liver Transplantation
View of Cerebral Perfusion in Liver Transplantation
Investigator's aim in this study is to compare the more accessible and low-cost Carotid Doppler USG measurements, which are relatively more difficult to access, costly, and have technical disadvantages, and to demonstrate their…
- Conditions
- End-stage Liver Disease (ESLD), Liver Transplantation, Cerebral Perfusion, Intraoperative Monitoring
- Trial name
- NIRS/Doppler (NCT07442214)
- Testing
- Carotid Doppler Ultrasonography and Near-Infrared Spectroscopy (NIRS)
- Where
- Turkey (Türkiye)
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Inonu University
Liver Transplantation, Tranexamic Acid
Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial
We propose a multi-center randomized trial to test the primary hypothesis that tranexamic acid is superior to placebo on blood loss in adult orthotopic liver transplantation within the initial 24 hours and that tranexamic acid is…
- Conditions
- Liver Transplantation, Tranexamic Acid, End-stage Liver Disease (ESLD)
- Trial name
- ESTA (NCT07157631)
- Testing
- tranexamic acid, 0.9 % saline
- Where
- China
- Volunteers
- 1,546 people
- Sponsor
- RenJi Hospital
End-stage Liver Disease (ESLD), Liver Transplant
A Physical Activity Program in End-state Liver Disease
The primary aim of this study is to improve both physical fitness and sarcopenia of patients with ESLD who are potentially eligible for liver transplantation through a 12-week physical training program.
- Conditions
- End-stage Liver Disease (ESLD), Liver Transplant, Sarcopenia, Poor Physical Fitness
- Trial name
- NCT02776553
- Testing
- Nutritional consultation, Physical training program, Behavioral modification therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Arkansas